» Authors » Tommy A Rinkoski

Tommy A Rinkoski

Explore the profile of Tommy A Rinkoski including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 100
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Saha S, Skeie J, Schmidt G, Eggleston T, Shevalye H, Sales C, et al.
Redox Biol . 2024 Sep; 77():103348. PMID: 39332053
Fuchs endothelial corneal dystrophy (FECD), the leading indication for corneal transplantation in the U.S., causes loss of corneal endothelial cells (CECs) and corneal edema leading to vision loss. FECD pathogenesis...
2.
Roddy G, Kohli D, Niknam P, Omer M, Chowdhury U, Anderson K, et al.
Ophthalmol Sci . 2024 Sep; 5(1):100590. PMID: 39328825
Purpose: To investigate subconjunctival administration of a single-stranded, adeno-associated virus, serotype 2, engineered to express stanniocalcin-1 with a FLAG tag (ssAAV2-STC-1-FLAG) as a novel sustained (IOP) lowering agent with a...
3.
Roddy G, Chowdhury U, Anderson K, Rinkoski T, Hann C, Chiodo V, et al.
PLoS One . 2022 May; 17(5):e0269261. PMID: 35639753
Glaucoma is the leading cause of irreversible blindness worldwide. Therapies for glaucoma are directed toward reducing intraocular pressure (IOP), the leading risk factor and only reliable therapeutic target via topical...
4.
Wieben E, Aleff R, Rinkoski T, Baratz K, Basu S, Patel S, et al.
PLoS One . 2021 Dec; 16(12):e0260837. PMID: 34855896
Expansion of CTG trinucleotide repeats (TNR) in the transcription factor 4 (TCF4) gene is highly associated with Fuchs Endothelial Corneal Dystrophy (FECD). Due to limitations in the availability of DNA...
5.
Rinkoski T, Bahler C, Pacheco J, Khanna M, Holmes D, Chowdhury U, et al.
PLoS One . 2021 Sep; 16(9):e0258006. PMID: 34587219
Primary cultures of human corneal endothelial cells (HCECs) are an important model system for studying the pathophysiology of corneal endothelium. The purpose of this study was to identify and validate...
6.
Chowdhury U, Kudgus R, Holman B, Rinkoski T, Hann C, Bahler C, et al.
J Ocul Pharmacol Ther . 2021 Mar; 37(5):251-260. PMID: 33784195
To evaluate pharmacokinetic parameters and ocular hypotensive effects of cromakalim prodrug 1 (CKLP1) in normotensive large animal models. Optimal CKLP1 concentration was determined by dose response and utilized in short-...
7.
Xu T, Li Y, Afshari N, Aleff R, Rinkoski T, Patel S, et al.
Invest Ophthalmol Vis Sci . 2021 Jan; 62(1):17. PMID: 33444430
Purpose: To characterize inheritance, penetrance, and trinucleotide repeat expansion stability in Fuchs endothelial corneal dystrophy (FECD). Methods: One thousand unrelated and related subjects with and without FECD were prospectively recruited....
8.
Roddy G, Rinkoski T, Monson K, Chowdhury U, Fautsch M
PLoS One . 2020 May; 15(5):e0232591. PMID: 32365129
Prostaglandin F2 alpha (PGF2α) analogues such as latanoprost are common first-line intraocular pressure (IOP) lowering medications. However, their clinical use is limited in some patient populations due to minimal or...
9.
Chowdhury U, Kudgus R, Rinkoski T, Holman B, Bahler C, Hann C, et al.
PLoS One . 2020 Apr; 15(4):e0231841. PMID: 32298376
Elevated intraocular pressure is the only treatable risk factor for glaucoma, an eye disease that is the leading cause of irreversible blindness worldwide. We have identified cromakalim prodrug 1 (CKLP1),...
10.
Soragni E, Petrosyan L, Rinkoski T, Wieben E, Baratz K, Fautsch M, et al.
Invest Ophthalmol Vis Sci . 2018 Apr; 59(5):1888-1896. PMID: 29677349
Purpose: The strongest genetic association with Fuchs' endothelial corneal dystrophy (FECD) is the presence of an intronic (CTG·CAG)n trinucleotide repeat (TNR) expansion in the transcription factor 4 (TCF4) gene. Repeat-associated...